|
The Hindu
Press release at The Hindu, 21.06.2011, Chennai By
Special Correspondent
The Hindu, 21.06.2011, Chennai
- K. P. Mundhra
Executive Director, Albert David said the company's
formulations, Placentrex (gel and injection) is the
only human placenta based product in the country
developed through indigenous research. He added that
not a single negative adverse drug reaction or side
effect had been noted in the 60 years of the use of
the injection and 11 years' use of the gel. The
placentas are collected from multiple city hospitals
in Kolkata, thanks to a special arrangement with the
State's Health and Family Welfare Ministry. About
300 placenta are collected every single day,
refrigerated, transported to the factory, where they
are stored for seven days after which the process of
extraction begins. During the processing, the
product is tested at three stages for harbouring
viruses or bacteria. "At the temperature we use as
part of our patented process, it is impossible for
these organisms to survive," he said.
Times of India
Press release at The Times of India 21.06.2011,
Chennai By Times News Network
The Times of India, 21.06.2011, Chennai
- "We proved
that the placenta we used were safe and tested.
There are no side effects to this drug and there are
no alternatives. Antibiotics can cure infections but
can not treat inflammations. Doctors have trusted
our drug. Said K. P. Mundhra, Executive Director of
Albert David, which manufactures Placentrex. The
cost of the injection is Rs.41 per ampoule, and
Rs.50 for a tube of gel. For treatment of Pelvic
inflammations a woman would need 15 ampoules.
The Economics Times
Albert David to set up unit with R&D facility The
Economic Times dated 18.1.2000, Sutapa Raha,Kolkata,
17th January
Keeping the heady days of the post
- TRIPS era and
product patent regime in mind, drug manufacturers
back home are slowly drawing up strategies for
survival and good health.
A case in point is the decades old Kolkata - headquartered,
Albert David Ltd, which is not only setting up a new
manufacturing unit bundled with an R&D facility but
is also eyeing licensing agreements with
pharmaceutical companies abroad.
K. P. Mundra, Executive Editor of Albert David Ltd.,
told ET : "With more and more MNCs entering the
pharmaceutical market in India, we need to have
state-of-the-art technologies for production of
quality products and thereby meet competition
head-on. Our R&D facility will also have to be
strengthened."
To begin with, Albert David is setting up a new
factory in Kolkata with an investment of Rs 40 crore.
The unit will club the company's R&D centre, for
advanced research on formulations. Investment will
be in phases and the project will be partly funded
by the company's own earnings and partly by
different FIs.
Speaking about the new project, Mr. Mundhra said:
"We already manufacture a wide range of
formulations, large volume parentals and medical
disposables. Now the IV fluid market is very
competitive and the market is only growing by 8-10
percent a year. Therefore, we would concentrate on
the formulations market."
"This new facility would manufacture oral liquids,
tablets, ointments and some bulk drugs. Our aim is
to increase our present production and launch more
and more new products every year. With a strong R&D
we hope to do that," he added.
The company is also looking at some licensing
tie-ups with foreign pharma companies who have not
yet entered the Indian market.
Pharmacon
Albert David to set up a new mfg facility at Kolkata,
Pharmacon dated 24.02.2000
The new facility, which would commence operations
tentatively by 2002, would manufacture oral liquids,
tablets, ointments and some bulk drugs. "The aim is
to increase the present production and launch more
and more new products every year and with a strong
R&D team we hope to achieve it," Mundhra added.
Joy Roy Choudhury, Kolkata
In the post - TRIPs era Indian drug manufacturers are
realigning their survival strategies. With more and
more MNCs entering the domestic market and keeping
the product patent regime ahead, domestic
manufacturers are drawing up strategies for their
sustainable growth and survival.
The decades old Kolkata-based Albert David Ltd., a
leading and fast growing professionally managed
pharmaceutical company is setting up a new
manufacturing facility along with an advanced R&D
facility as a part of its modernisation and
upgradation plans.
The company is also in the final stages of
negotiations with foreign pharma companies for
licensing agreements.
K.P. Mundhra, executive director of Albert David
Ltd. in an exclusive interview to Express Pharma
Pulse said. "As more and more MNCs are entering the
pharma market in India we cannot afford to sit idle.
We need to upgrade our manufacturing facilities and
have state-of-the-art technologies for production of
quality products so that we can meet the challenges
posed by the MNCs. So for these our R&D facility
will also have to be strengthened."
The company will be finalising the exact location of
the new factory to be set up in Kolkata within two
months. The cost of the entire project has been
pegged at Rs 40 crore. The investment will be in
phases now and the project will be partly funded by
the company's own earnings and partly by different
FIs.
Albert David has multi-centric manufacturing plants
located in Kolkata, Ghaziabad and Mandideep near
Bhopal (MP). The manufacturing units of the company
have been accorded WHOGMP accreditation. The bulk
drug manufacturing facility has been approved by US
FDA.
Albert David ranked 58th out of 16,000 plus pharma
companies is a part of the Kothari Group of
companies.
"We manufacture and market a wide range of
formulations, large volume parenterals and medical
disposables. We would concentrate on the
formulations market," Mundhra informed.
Some of the products are regularly exported to
different countries including the United States and
Europe. At present the company is operating in major
therapeutic segments, herbal drugs, anti-bacterials,
nutrition, anti-ulcerants, neurotropics, placental
extracts, anxiolytics, small and large volume
parenterals, dermatologicals and disposable syringes
and needles. Albert David is a leader in human
placental extract therapy.
Exp Pharma Pulse
Albert David to set up a new mfg facility at Kolkata,
Express Pharma Pulse dated 27.1.2000
As more and more MNCs are entering the Indian
pharmaceuticals market we cannot afford to sit idle.
We need to upgrade our manufacturing facilities and
have state-of-art technologies for the production of
quality products so that we can meet the challenges
posed by MNCs.
EPP Team Kolkata
In the post -TRIPS era, Indian drug manufacturers are
realigning their survival strategies. With more and
more MNCs entering the domestic market and keeping
the product patent regime ahead, domestic
manufacturers are drawing up strategies for their
sustainable growth and survival.
Kolkata-based Albert David Ltd. a leading and fast
growing professionally managed pharmaceutical
company is setting up a new manufacturing facility
along with an advanced R&D facility as a part of its
modernization and upgradation plans.
The company is also in the final stages of
negotiations with foreign pharma companies for
licensing agreements. "As many more MNCs are
entering the Indian pharmaceuticals market we cannot
afford to sit idle. We need to upgrade our
manufacturing facilities and have state-of-art
technologies for the production of quality products
so that we can meet the challenges posed by MNCs.
So, for these, our R&D facility will also have to be
strengthened," said K. P. Mundhra, Executive
Director, Albert David.
The company will be finalizing the exact location of
the new factory to be set up at Kolkata soon. The
cost of the project estimated at Rs 40 crore, will
be funded by the company's own earnings and partly
by different financial institutions. Albert David
has multicentric manufacturing plants located in
Kolkata, Ghaziabad and Mandideep near Bhopal in
Madhya Pradesh. The manufacturing units of the
company have been accorded WHO-GMP accredition. The
bulk drug manufacturing facility has been approved
by the US FDA.
Albert David, ranked 58th out of 16,000 plus pharma
companies, is a part of the Kothari Group of
companies. "We manufacture and market a wide range
of formulations, large volume parentals and medical
disposables. We would concentrate of the
formulations market," informed Mundhra.
Some of the company's products are regularly
exported to different countries including the United
States and Europe. At present, the company operates
in major therapeutic segments like analgesics,
herbal drugs, anti-bacterials, nutrition, anti-ulcerants,
neurotropics, placental extracts, anxiolytics, small
and large volume parentals, dermatologicals and
disposable syringes and needles. Albert David is a
leader in human placental extract therapy. The new
facility, which is likely to commence its operations
by 2002, is to manufacture oral liquids, tablets,
ointments and some bulk drugs.
"The aim is to increase the present production and
launch more and more new products every year and
with a strong R&D team we hope to achieve this,"
Mundhra added. The company is in the advanced stages
of negotiations with several foreign pharmaceutical
companies and multi-nations for technical and
licensing tie-ups. Mundhra declined to divulge the
details at this stage.
Pharma Pulse
Albert David to set up facility to manufacture oral
solids and liquids, Pharma Pulse dated 12.8.2004
CITY - BASED pharmaceutical company Albert David
Limited, established more than seven decades ago, is
planning to set up a new state-of-the-art
manufacturing facility on the outskirts of the city
as a part of its modernization and up gradation
plans. Currently, the company manufactures and
markers a wide range of pharmaceutical finished
dosage form for different therapeutic segments,
medical disposables and a wide-range of IV fluids.
Confirming the development, Kamal Prasad Mundhra,
executive director of Albert David Limited told
Express Pharma Pulse, "The company has decided on
principle to set up a state-of-the-art manufacturing
facility in and around the city". "We are already
scouting for proper land to set up this new
manufacturing facility, which will adhere to all the
international specifications like Cgmp, WHO & FDA
norms, "he informed. "We will be soon zeroing on the
land and the construction will commence immediately.
The new facility to be set up at a cost of Rs. 40
crore, is likely to come up in the next two years
time, "Mundhra added. "The new facility is likely to
manufacture oral solids and liquids, ointments and
some bulk drugs. The state-of-the-art manufacturing
facility will help us to substantially bring down
the per unit cost of production of medicine", he
said.
The company has also decided to upgrade its R&D has
also decided to upgrade its R&D facilities. The new
R&D facility will e housed in the proposed
manufacturing unit. Albert David Limited, is a part
of the GD Kothari Group of companies having diverse
interests in textiles, engineering items, tea
plantations, chemicals, salt processing and
international trading. The company's turnover stood
at Rs. 115 crore in the last financial year
(2003-04). The company exports its products to
countries in Europe, Africa and in the US. At
present, the company is operating in major
therapeutic segments like NS-AIDs, herbal drugs,
anti-bacterials, anti-ulcerants, neurotropics,
anxiolytics, small and large volume parentals,
dermatological products and disposable syringes and
needles. The company is a leader in human placental
extract therapy. Placentrex, one of the
largest-selling products of the company is
celebrating its 'golden jubilee' this year :
In a related development, the company has also
decided to increase the production capacity of its
Ghaziabad factory in Uttar Pradesh producing a wide
range of IV fluids.
|
